Taysha Gene Therapies Current Ratio 2020-2023 | TSHA
Taysha Gene Therapies current ratio from 2020 to 2023. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Taysha Gene Therapies Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2023-12-31 |
$0.15B |
$0.04B |
4.08 |
| 2023-09-30 |
$0.17B |
$0.18B |
0.95 |
| 2023-06-30 |
$0.05B |
$0.05B |
1.07 |
| 2023-03-31 |
$0.07B |
$0.05B |
1.33 |
| 2022-12-31 |
$0.10B |
$0.06B |
1.54 |
| 2022-09-30 |
$0.04B |
$0.03B |
1.30 |
| 2022-06-30 |
$0.08B |
$0.04B |
1.79 |
| 2022-03-31 |
$0.11B |
$0.05B |
2.20 |
| 2021-12-31 |
$0.16B |
$0.05B |
3.08 |
| 2021-09-30 |
$0.20B |
$0.04B |
4.56 |
| 2021-06-30 |
$0.21B |
$0.03B |
7.30 |
| 2021-03-31 |
$0.24B |
$0.02B |
12.64 |
| 2020-12-31 |
$0.26B |
$0.01B |
36.17 |
| 2020-09-30 |
$0.28B |
$0.01B |
24.02 |
| 2020-06-30 |
$0.00B |
|
0.00 |
| 2020-03-31 |
$0.00B |
|
0.00 |
| 2019-12-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.430B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
